Welcome, Guest. Please login or register.
December 01, 2022, 02:45:11 pm

Login with username, password and session length


Members
Stats
  • Total Posts: 766835
  • Total Topics: 65454
  • Online Today: 206
  • Online Ever: 5484
  • (June 18, 2021, 11:15:29 pm)
Users Online
Users: 3
Guests: 168
Total: 171

Welcome


Welcome to the POZ Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Do I Have HIV?” posting guidelines. Click here for posting guidelines pertaining to all other POZ community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: BANNER trial - N6LS - Neutralizing Antibody Shows Promise  (Read 165 times)

0 Members and 1 Guest are viewing this topic.

Offline Jim Allen

  • Administrator
  • Member
  • Posts: 19,791
  • Twitter @JimAllenDublin
    • HIV Lessons
BANNER trial - N6LS - Neutralizing Antibody Shows Promise
« on: November 23, 2022, 11:55:07 am »

POZ.com in full: https://www.poz.com/article/broadly-neutralizing-antibody-shows-promise-hiv-treatment

In short:

Quote
The experimental antibody, dubbed N6LS, demonstrated strong antiviral activity in a Phase II study.

A single infusion of N6LS, an experimental broadly neutralizing antibody (bnAb) from ViiV Healthcare, demonstrated robust antiviral activity as good as or better than that of other investigational bnAbs, offering hope for a new long-acting HIV treatment option, researchers reported at the HIV Drug Therapy meeting in Glasgow. Among 14 previously untreated study participants who received a high or low dose of N6LS, 13 had a virological response.

N6LS, also known as VH3810109, targets the CD4 binding site on HIV’s outer envelope, thereby preventing the virus from entering CD4 T cells. The antibody has demonstrated broad and potent neutralizing activity in laboratory studies.

Peter Leone, MD, of ViiV, and colleagues evaluated the safety, pharmacokinetics and antiviral activity of N6LS in the Phase IIa BANNER trial.

All participants received a single intravenous infusion of N6LS, either a weight-based dose of 40 milligrams per kilogram or a fixed dose of 280 mg, which works out to approximately 4 mg/kg—about one tenth the weight-based dose. The researchers assessed viral suppression while N6LS was used alone, known as monotherapy. People who did not reach a viral load below 0.5 log (about 3 copies/mL) by day 11 or experienced viral rebound after an initial response started antiretroviral therapy right away; all remaining participants started standard treatment at day 84.
HIV 101 - Everything you need to know
HIV 101
Read more about Testing here:
HIV Testing
Read about Treatment-as-Prevention (TasP) here:
HIV TasP
You can read about HIV prevention here:
HIV prevention
Read about PEP and PrEP here
PEP and PrEP

 


Terms of Membership for these forums
 

© 2022 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.